Avid Bioservices Inc (CDMO)

[vinmantoo]

"We find that a live attenuated vaccine prevents virus replication" — so "this could be a game changer in controlling SARS-CoV-2 transmission."

There is a lot of resistance to live attenuated virus vaccines in the general public. Hell, FluMIST is a live attenuated cold-adapted Flu vaccine which only replicated in the nasal cavity. It struggled to gain sales and can be considered a flop. I made some money from my investment in AVIR and after it was bought by MEDI but it wasn't the major success I had hope for. Now with social media and the cabal of anti-vaxxers, I have my doubt that any attenuated virus Covid vaccine would gain wide acceptance.

My money is ENTA's Covid anti-viral EDP-235, which is in a phase trial and the data should be out on about a month. It is far more potent than Paxlovid, has much higher tissue distribution in the lungs than Paxlovid, and animal studies shows it blocks communal transmission, something Paxlovid failed to do. EDP-235 also is once a day pill and doesn't need ritonavir to block drug efflux pumps like Paxlovid does as part of its 6 pills a day regimen. Add in that the pre-clinical EDP-235 data suggest it my not have the problem of Covid rebound like Paxlovid. It is no sure thing but do I like the odds.